IFPMA
25.9.2018 09:02:13 CEST | Business Wire | Press release
WIPO and the research-based pharmaceutical industry today launched a new online tool designed to help procurement agencies better understand the global patent status of medicines.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180925005088/en/
The Patent Information Initiative for Medicines (Pat-INFORMED) is a unique resource where patent holders provide information about patents covering approved medicines through a free, open access database.
This new public database became operational today, along with a platform where procurement agencies can make direct enquiries to companies.
Pat-INFORMED is a partnership between WIPO and the International Federation of Pharmaceutical Manufacturers and Associations, IFPMA, the global trade association representing the research-based pharmaceutical industry. Pat-INFORMED originated in the industry’s efforts to add clarity to patent information about medicines. WIPO’s globally recognized expertise in the organization and public dissemination of patent data will make an important contribution to the accessibility of patent information.
WIPO is hosting the database and providing the resources to ensure its continued development, while IFPMA is working closely with the 20 leading research-based biopharmaceutical companies that have backed this initiative to help ensure a consistent and coordinated approach.
“WIPO is committed to increasing the transparency of the patent system and ensuring it works to benefit humankind. As a public-private partnership focusing on access to key patent information, Pat-INFORMED will facilitate the procurement of important medicines and thereby support better health outcomes for people across the globe. Such partnerships are critical to success in the field of public health," said WIPO Director General Francis Gurry. “WIPO is pleased to be contributing its extensive expertise in making complex patent information simpler and more accessible and looks forward to further collaboration with the pharmaceutical industry to ensure the success of this initiative.”
While information about patent applications and grants reside in the public domain, resources that directly link patents to medicines already on the market are scarce and limited. Tools that directly link granted patents to medicines are only available publicly in certain countries (e.g. the USA’s ‘Orange Book’) or through private third-party databases. Pat-INFORMED aims to help close these gaps and make patent research easier, faster and more accessible to a wider array of health workers.
Importantly, Pat-INFORMED also offers procurement agencies a direct communication channel for follow-on enquiries to participating companies. Each of the participating companies, currently 20, has agreed to engage in discussions with official procurement agencies that are seeking more detailed information about granted patents on specific products.
So far, Pat-INFORMED houses information on over 14,000 individual patents, for 600 patent families and 169 INNs, unique names that are globally recognized and used to identify pharmaceutical substances or active pharmaceutical ingredients within medicines that cover a wide range of conditions.
“This initiative is a practical way of reducing the complexity around access to patent information, something health experts have long been calling for. By easing access to patent information for public health authorities, Pat-INFORMED can help them take more informed decisions about procurement options available to them, and will be an important contribution to global health,” said Thomas Cueni, Director General IFPMA. “The task of retrieving and uploading over 14,000 individual national patents has been considerable; but now that the process and platform are in place, I’m confident that we can continue to increase the database’s scope to more INNs than the current 160.”
“More-efficient procurement processes save lives by getting medicines to people more quickly,” said Wesley Kreft, Director, Global Supply Chain, i+solutions, a Netherlands-based not-for-profit organization specializing in medical supply chain management for developing countries, including many recipients of Global Fund grants. Speaking of his work, Mr. Kreft said: “Pat-INFORMED has the potential to reduce by 30 percent the time required to procure medicines for low and middle income countries.”
Pat-INFORMED features patent information for small molecule drugs within oncology; hepatitis C, cardiovascular, HIV, diabetes, and respiratory therapy areas; and any products on the WHO Essential Medicines List that are not within these therapy areas. In a second phase, the initiative will extend to all therapeutic areas and explore the inclusion of complex therapeutics.
The launch took place at an event on the sidelines of the 2018 Assemblies of the Member States of WIPO.
About WIPO
The World Intellectual Property Organization (WIPO) is the global forum for intellectual property policy, services, information and cooperation. A specialized agency of the United Nations, WIPO assists its 191 member states in developing a balanced international IP legal framework to meet society's evolving needs. It provides business services for obtaining IP rights in multiple countries and resolving disputes. It delivers capacity-building programs to help developing countries benefit from using IP. And it provides free access to unique knowledge banks of IP information.
About IFPMA
IFPMA represents research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry's two million employees discover, develop, and deliver medicines and vaccines that improve the lives of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180925005088/en/
Contact:
IFPMA Sadia Kaenzig, Tel: +41 79 513 4442 Communications Manager: Email: s.kaenzig@ifpma.org or IFPMA Morgane de Pol, Tel: +41 79 962 11 95 Communications Manager Email: m.depol@ifpma.org or Media Relations WIPO: Tel: (+41 22) 338 81 61 / 338 72 24 E-mail: Publicinf@wipo.int
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Nordic Firms Seek Green, Sovereign AI Infrastructure14.7.2026 11:00:00 CEST | Press release
Renewable power, heat reuse and local data requirements are reshaping private and hybrid cloud choices, ISG Provider Lens® report says Nordic enterprises are adopting private and hybrid cloud infrastructure that combines AI-ready capacity, local residency and low-carbon operations as high-performance workloads and geopolitical risk reshape IT strategies, according to a new research report published today by Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm. The 2026 ISG Provider Lens® Private/Hybrid Cloud — Data Center Services report for the Nordics finds that the region is evolving from a hosting destination into a backbone for European data processing. Enterprises are using the Nordics’ renewable energy and natural cooling to support cloud strategies that balance large scale with environmental consciousness and compliance with data sovereignty regulations. “Nordic enterprises are connecting infrastructure decisions to resilien
European Commission Approves Erbitux® (cetuximab) in Combination with Encorafenib and FOLFOX for First-Line Treatment of Metastatic Colorectal Cancer with BRAF V600E Mutation14.7.2026 11:00:00 CEST | Press release
ERBITUX in combination with encorafenib and FOLFOX is the first and only approved targeted regimen for the first-line treatment of adult patients with BRAF V600E-mutant mCRCThe approval is based on the pivotal Phase 3 BREAKWATER trial, which demonstrated statistically significant and clinically meaningful improvements in both progression-free survival (PFS) and overall survival (OS) compared to standard chemotherapy with or without bevacizumabERBITUX confirms its status as the pioneering anti-EGFR therapy in mCRC, now approved across different patient populations and multiple lines of therapyNot intended for Canada-, UK- or US-based media Merck, a leading global science and technology company, today announced that the European Commission (EC) approved an update to the Erbitux (cetuximab) EU label on June 26, 2026. Erbitux is now indicated in combination with encorafenib for patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) — both in first-line treatment in combination
Swiss Pension Funds Increase Commitments to Record Infrastructure Equity Fund to EUR 1.23 Billion14.7.2026 09:58:00 CEST | Press release
Record Asset Management GmbH (RAM), subsidiary of London-listed Record plc (Record Financial Group), today announced that its Infrastructure Equity fund has attracted EUR 160 million of additional capital from Swiss pension funds, increasing total commitments to approximately EUR 1.23 billion. Capital deployment continues to progress in line with expectations, with more than one-third of the fund’s initial capital now deployed or committed to investments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713541233/en/ RAM manages a dedicated infrastructure co-investment vehicle in partnership with APG, the pension asset manager of ABP, providing Swiss pension funds with access to large-scale infrastructure equity investments alongside APG’s pension fund partners. RAM is the European asset management arm of Record Financial Group, the London-listed specialist investment group managing USD 115 billion of assets on behalf of in
Samsung Becomes a Sisvel Wi-Fi Multimode Pool Licensee and Licensor14.7.2026 09:09:00 CEST | Press release
Samsung Electronics has signed up as a licensee of the Sisvel Wi-Fi Multimode pool and has also become a licensor under the programme. The decision by the South Korean company - a global R&D powerhouse and among the world’s top smartphone vendors, as well as a leader in many other electronic product categories - not only confirms the Sisvel Wi-Fi Multimode pool as a recognised solution provider for parties seeking to derisk Wi-Fi implementation but also considerably expands the scope of the programme’s patent offering. Since it was publicly launched in January 2026, ASUS, Hewlett Packard Enterprise, Microsoft and Sony Group Corporation have become licensees of the Sisvel Wi-Fi Multimode pool. There are also five licensor/licensee companies: Huawei, Panasonic, Philips, Samsung Electronics and ZTE. The other licensors are KPN, Mitsubishi Electric, Orange, Aegis 11 SA, SK Telecom and Wilus. The agreement announced today ends litigation in the Eastern District of Texas between Samsung Elec
Wolters Kluwer Integrates Legal Intelligence Platform With Libra Legal AI Workspace in the Netherlands14.7.2026 09:00:00 CEST | Press release
Dutch legal professionals gain access to additional content sources in the Libra by Wolters Kluwer AI workspace, powering a new generation of AI-driven legal work Wolters Kluwer Legal & Regulatory today announced the integration of its Legal Intelligence multi-content-provider platform with the Libra by Wolters Kluwer AI workspace in the Netherlands. Dutch legal professionals will now be able to access more than 5000 additional pieces of expert legal content from Wolters Kluwer and third-party content providers as well as public sources in addition to the existing content offerings in Libra. “By bringing Legal Intelligence into Libra, we move beyond traditional search to truly integrated, AI-driven workflows,” said Rimco Spanjer, Vice President & Managing Director, Wolters Kluwer Legal & Regulatory Benelux. “Combining our authoritative content with trusted third-party sources in one AI workspace enables legal professionals to work smarter every day.” The integration will include truste
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
